<code id='77255445D2'></code><style id='77255445D2'></style>
      • <acronym id='77255445D2'></acronym>
      <center id='77255445D2'><center id='77255445D2'><tfoot id='77255445D2'></tfoot></center><abbr id='77255445D2'><dir id='77255445D2'><tfoot id='77255445D2'></tfoot><noframes id='77255445D2'>
      • <optgroup id='77255445D2'><strike id='77255445D2'><sup id='77255445D2'></sup></strike><code id='77255445D2'></code></optgroup>
        5. <b id='77255445D2'><label id='77255445D2'><select id='77255445D2'><dt id='77255445D2'><span id='77255445D2'></span></dt></select></label></b><u id='77255445D2'></u>
          <i id='77255445D2'><strike id='77255445D2'><tt id='77255445D2'><pre id='77255445D2'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / fashion / entertainment      
           
     
           
      
          entertainment 
           
      
           
      
           
       2025-10-06 09:24:21 
   
      
           
      
           
                        
          entertainment  
          
                                   
                 
                                      author：comprehensive   
                                        
                                      
                                      Page View：9
                                  
                                    
          
                                   
          Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT
          Darron Cummings/AP
          A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.
          Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.
          advertisement
          Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe													Log In											
                      
                              
          
                                 Previous article：

                                
                                          FTX founder Sam Bankman
                                
                            
          Next article：  
                                      
                                          Psychedelics group wrestles with new pharma identity
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles